We have just launched NXtec D008 DMD – the first dedicated neuromuscular assay to be added to our digitalMLPA™ catalogue – designed for the reliable detection of CNVs in the DMD gene. Read more.
Visit us at booth 404 during ESHG 2026, taking place 13-16 June in Gothenburg (Sweden), and discover how our products can support critical clinical questions and accelerate your research. Read more.
Our digitalMLPA™ portfolio is about to receive an update with the upcoming launch of NXtec D008 DMD – our first dedicated neuromuscular digitalMLPA assay. Read more.
We have just launched NXtec D008 DMD – the first dedicated neuromuscular assay to be added to our digitalMLPA™ catalogue – designed for the reliable detection of CNVs in the DMD gene. Read more.
We have successfully obtained our certification under the new In Vitro Diagnostic Regulation (IVDR; 2017/746)! The first batch of flagship products are already available on the market under the new IVDR, well in advance of the transition period deadline. Read more.
D007 Acute Lymphoblastic Leukemia was recognized as a valuable tool for enhanced molecular testing of adult ALL cases in work shown recently at a scientific congress. Read more.
Join our mailing list to receive the latest information about our products, technologies and website.